Navigation Links
Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
Date:1/3/2008

implant.

According to the latest statistics published by the Pennsylvania Health Care Cost Containment Council (PHC4), one of the few U.S. States mandated to collect such data, patients that contracted a surgical site infection spent an average of 14.5 days in hospital at an average hospital charge of $132,110 compared to 4.7 days and $33,267 for patients that had no hospital-acquired infection. The same official report states that "surgery performed on the large and small intestines represented the largest percentage of surgical site infections at 9.0% followed closely by surgery for blockages in blood vessels, including blood vessels of the heart, which accounted for 8.9%". Independent market research recently performed by L.E.K. Consulting has conservatively projected peak US sales of GENTAMICIN SURGICAL IMPLANT to be greater than US$200 million per annum.

Dr. Michael Myers, Innocoll's President and CEO commented, "As an already approved product in Europe and elsewhere with proven safety, efficacy and pharmacoeconomics, we believe that the development of our Gentamicin Implant for the US market represents an excellent commercial opportunity and value proposition for our shareholders. The commencement of this phase 3 trial, our first in the US, is a landmark event for the Company and demonstrates our full commitment to the clinical development of our exciting pipeline of products."

About Innocoll, Inc.

Innocoll is a privately held, specialty pharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. It develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R) and Liquicoll(R). Innocoll 's lead product, Gentamicin Surgical Implant for the treatment and prevention of surgical site infections, is approved for sale in 49 countries in Europe, Latin America, Middle East, Africa and Asia and is marketed under
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... MONMOUTH JUNCTION, N.J. , Jan. 23, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... surgery patients, announced the receipt of $385,642, net ... approved participant of the Technology Business Tax Certificate ...
(Date:1/23/2015)... LONDON and BOSTON , January ... structure-guided drug discovery and development company, is delighted to announce ... has been awarded to Miles Congreve (Vice President ... co-founder) and Malcolm Weir (Chief Executive Officer and ...
(Date:1/22/2015)... 22, 2015  BiOptix is pleased to announce the appointment ... of Chemistry and Biochemistry. Scott joins the company after previous ... Amgen throughout the course of his nearly 20 year ... is a nationally recognized thought leader in the biosensor ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
(Date:1/22/2015)... Deer Path of Huntley -- a BMA affordable assisted ... 3 p.m. to 4 p.m. on Feb. 13. , The community, ... adults with physical disabilities between the ages of 22 and 64. ... and sweetheart-themed karaoke. , For more information about the event or ...
(Date:1/22/2015)... Va. (PRWEB) January 22, 2015 Liberty University ... Counseling (M.A.) program from the Council for Accreditation ... program, part of Liberty’s Center for Counseling & Family ... founding dean of the university’s new School of Behavioral Sciences. ...
(Date:1/22/2015)... West Hollywood, California (PRWEB) January 22, 2015 The ... 22, 2015 at 10 a.m., to commemorate the 42nd anniversary of ... the United States. , “It’s been 42 years since the Roe ... to choose is still as present as ever,” said City of ...
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... 23, 2015 VogueQueen is a seasoned and ... and many designers are thrilled to have it lead the ... its new collection of prom dresses for the global market. ... the strategic vision and he focuses on continuing the goal ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2
... Omnicell, Inc. (Nasdaq: OMCL ), a leading provider of system solutions ... 2009 to discuss Omnicell,s Third Quarter 2009 financial results. , ... conference call and webcast, When: October 22, ... Lipps, chairman, president and chief executive officer, ...
... calling on all Virginia restaurants and other workplaces to ... report by the Institute of Medicine (IOM) that concluded ... save lives. , (Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) , The ... conclusive evidence that secondhand smoke causes heart disease and ...
... , NEW YORK, Oct. 16 It,s open enrollment ... healthcare and other benefits. Sometimes when a serious ... health or disability insurance. Here,s more on making ... battling a major illness. , Listen to this report ...
... SOS Assistance, Inc. today was awarded the contract to provide ... TRICARE Overseas Program. Since 1998, International SOS has supported TRICARE ... receive the highest quality care, no matter where their work ... Rico. , Under this new contract, which includes ...
... MILWAUKEE, Oct. 16 Delays in shipments from vaccine ... Wisconsin to suspend its seasonal flu vaccination clinics throughout ... , The Shoo the Flu & Pneumonia Too! ... The clinics will resume as soon as additional ...
... ... ... than 30 pediatric experts from Children’s National Medical Center will be presenting at ... – 19 in Washington. , , , , ,Children’s pediatric specialists will be discussing many ...
Cached Medicine News:Health News:Omnicell to Release Third Quarter 2009 Earnings Results on October 22 2Health News:Virginia Restaurants Urged to Go Completely Smoke-Free After Major Report Finds Smoke-Free Laws Prevent Heart Attacks 2Health News:Virginia Restaurants Urged to Go Completely Smoke-Free After Major Report Finds Smoke-Free Laws Prevent Heart Attacks 3Health News:International SOS Awarded TRICARE Overseas Program Contract 2Health News:Delays in Vaccine Shipments Will Force Suspension of Shoo the Flu Clinics 2Health News:Children's National Experts Presenting at American Academy of Pediatrics Conference, 2
... Traditionally, when choosing a non-contact diagnostic lens, ... wide field of view and high magnification. ... introduced by Volk Optical, doctors can have both ... widest field of view available in a non-contact ...
... is a 3.0mm single loaded suture anchor ... anchor barb catches on the cancellous bone ... "breaks" free. The small size is perfect ... used in rotator cuff repair where single ...
... Tac™ implantThe USS Sports Medicine™ E-Z Tac implant ... soft tissue to bone. The resorbable repair device ... bone and is used to reattach damaged soft ... a resorbable copolymer, a polyester derivative of lactic ...
... Soft Tissue Anchor 2 mm is a resorbable ... bone using sutures. The resorbable repair device is ... and is used to reattach damaged soft tissue. ... copolymer, derived from glycolide and lactide colored with ...
Medicine Products: